Continue Reading
Full article on Unknown
Co-Diagnostics Announces Reverse Stock Split
Market Intelligence Analysis
AI-Powered
Why This Matters
Co-Diagnostics, Inc. has announced a 1-for-30 reverse stock split to become effective on January 2, 2026, which may lead to increased stock price and reduced share count, potentially improving the company's market appearance.
Market Impact
Market impact analysis based on bullish sentiment with 80% confidence.
Sentiment
Bullish
AI Confidence
80%
Time Horizon
Short Term
Article Context
Note: This is a brief excerpt for context. Click below to read the full article on the original source.
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has filed a Certificate of Amendment to its Certificate of Incorporation (the "Amendment") to effect a reverse stock split of its common stock at a ratio of 1-for-30 shares. The reverse stock split will become effective at 12:01 a.m. ET on Friday, January 2, 2026. Co-Dx's common stock will conti
Original article published by
Unknown
on December 30, 2025.
Analysis and insights provided by AnalystMarkets AI.
Analysis and insights provided by AnalystMarkets AI.